Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001211074 | SCV001382596 | uncertain significance | Alstrom syndrome | 2022-10-17 | criteria provided, single submitter | clinical testing | This sequence change replaces isoleucine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 381 of the ALMS1 protein (p.Ile381Thr). This variant is present in population databases (rs199872225, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with ALMS1-related conditions. ClinVar contains an entry for this variant (Variation ID: 941316). Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Fulgent Genetics, |
RCV001211074 | SCV002783619 | uncertain significance | Alstrom syndrome | 2022-03-22 | criteria provided, single submitter | clinical testing | |
Gene |
RCV003227009 | SCV003923354 | uncertain significance | not provided | 2023-05-01 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Natera, |
RCV001211074 | SCV002080402 | uncertain significance | Alstrom syndrome | 2020-03-11 | no assertion criteria provided | clinical testing |